Table 3 Economic evaluation of the main COVID-19 clinical pathway, with the inclusion of Rehabilitation costs
From: COVID-19 and hospital management costs: the Italian experience
Clinical Pathway | Economic evaluation of the hospital clinical pathway [€] | Rehabilitation clinical pathway [€] | Total costs (Hospital pathway + Rehabilitation clinical pathway) [€] | Rehabilitation pathway impact on total costs [%] |
|---|---|---|---|---|
Clinical Pathway #1 (5.38% of patients) | 17,629.63€ | 5,802.00€ | 23,431.63€ | 24.76% |
Clinical Pathway #2 (15.84% of patients) | 10,941.41€ | 2,960.60€ | 13,902.01€ | 21.30% |
Clinical Pathway #3 (8.34% of patients) | 26,339.20€ | 5,802.00€ | 32,141.20€ | 18.05% |
Clinical Pathway #4 (29.06% of patients) | 10,778.04€ | 0.00€ | 10,778.04€ | 0.00% |
Clinical Pathway #5 (11.67% of patients) | 22,857.28€ | 2,960.60€ | 25,817.88€ | 11.47% |
Pathway #6 (9.01% of patients) | 3,421.47€ | 0.00€ | 6,198.02€ | 0.00% |
Pathway #7 (16.91% of patients) | 3,717.33€ | 2,960.60€ | 10,113.13€ | 29.27% |
Pathway #8 (3.79% of patients) | 8,900.42€ | 5,802.00€ | 21,346.32€ | 27.18% |